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astian Way, HKThe decision to administer a radical course of radiotherapy (RT) is largely inﬂuenced by the
dose-volume metrics of the treatment plan, but what are the patient-related and other factors
thatmay independently increase the risk of radiation lung toxicity?Poor pulmonary functionhas
been regarded as a risk factor and a relative contraindication for patients undergoing radical RT,
but recent evidence suggests that patients with poor spirometry results may tolerate conven-
tional or high-dose RT as well as, if not better than, patients with normal function. However,
caution may need to be exercised in patients with underlying interstitial pulmonary ﬁbrosis.
Furthermore, there is emerging evidence ofmolecularmarkers of increased risk of toxicity. This
review discusses patient-related risk factors other than dosimetry for radiation lung toxicity.
SeminRadiatOncol 25:100-109C2015 TheAuthors. Published byElsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Radiotherapy (RT) is a mainstay local treatment for non–small cell lung cancer. Radiation-induced lung toxicity
(RILT) is one of themost common dose-limiting toxicities from
thoracic irradiation, especially for patientswith lung cancerwho
require a high radiation dose and frequently have reduced lung
function caused by tumor or pre-existing lung diseases. RILT
includes radiation pneumonitis (RP) and pulmonary ﬁbrosis.
RP develops in the ﬁrst few weeks or months after RT with
symptoms of cough, shortness of breath, chest pain, and low-
grade fever. It can be reversible, but in severe cases, may be life
threatening. Pulmonary ﬁbrosis can develop even years after
RT, sometimes as a sequential effect of acute injury, leading to
permanent impairment of lung function. RP has been more
widely investigated than pulmonaryﬁbrosis because it develops
earlier and is thus more conveniently evaluated.
The risk of RILT for each individual patient remains unclear.
In general, it is related to clinical patient factors, inherited
biological factor, tumor factors, dosimetric parameters, andg/10.1016/j.semradonc.2014.12.003
015 The Authors. Published by Elsevier Inc. This is an open
ommons.org/licenses/by-nc-nd/3.0/).
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dose (MLD) have been consistently found to be related to RILT
and have beenwell documented.1,2 Patient-related factors have
also been investigated, and identifying those who have an
increased risk of RILT to tailor RT would make the treatment
safer and more beneﬁcial. In this review, we discuss the most
relevant risk factors other than dosimetry for RILT in patients
with lung cancer, including patient age, sex, smoking status,
pre-existing lung disease, pulmonary function (PF), previous
treatment, tumor location, genetic phenotypes, and inﬂam-
matory cytokines, to better select patients for RT or prescribe
radiation dose based on personalized toxicity estimate.Age
Older patients are believed to have poorer tolerance to RT and
are often given less aggressive treatment. Indeed, some studies3-7
and a pooled analysis of 13 studies before 20128 showed older
age signiﬁcantly increased the risk of RILT, but others did not
ﬁnd an association between age and the risk of RILT.9-13 A study
including 369 patients found that age (Z70 years) was an
independent predictor for both gradeZ2 (odds ratio [OR] ¼
1.99) and gradeZ3 RP (OR ¼ 8.90).4 Severe RP (gradeZ4)
was also more common in elderly patients, occurring in 1% of
those o70 years, compared with 6% of elderly patients.7
Another study found age (Z68 years) increased the risk of
gradeZ3 RP, and combining age with dosimetric factors and
pulmonary ﬁbrosis score improved the predictability of severe
RP.6 However, in a study of 576 patients by Jin et al,10 there wasaccess article under the CC BY-NC-ND license
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r60 and 460 years. It was not clear whether there was a
difference between patients r70 and 470 years. In all, age
should be considered a risk factor for RILT, but a clear cut-off
value may not exist owing to the heterogeneity among the older
patients. A comprehensive evaluation of other risk factors such
as comorbidities, performance status, frailty, and PF should be
done before making a determination on RT.Sex
The effect of sex on RILT is not clear. Women often have
smaller lung volumes than men do, and they are prone to have
autoimmunediseases thatmaypredispose them to a greater risk
of lung injury. It has been shown that the absolute lung volume
spared from 5 Gy (sV5) was signiﬁcantly associated with the
risk of RILT—the smaller the sV5, the higher the risk of RP.14
The sV5 would be smaller for women than for men given
similar radiation ﬁeld sizes. However, women also have, on
average, smaller tumor volumes.15 On the contrary, women are
often nonsmokers and thus have better lung reserve. A study
showed that sex was independently associated with gradeZ3
RP, 15% forwomen and 4% formen.11 In another study, when
using decision trees in the model, sex was selected as an input
variable in which women had higher risk of gradeZ2 RP.16
However, in most studies12-14,17,18 and a meta-analysis,8 no
association of sex with RP risk was seen. Therefore, sex should
not be given too much consideration when prescribing RT.Smoking Status
The association between smoking and RILT is controversial.
Smoking has been found to have a protective effect on the risk of
RILT in several studies10,12,19 and in a pooled analysis
(OR ¼ 0.65).8 Ongoing tobacco use,12 or current smokers,20
or recent quitters19 had less risk of RP than others. Jin et al found
in 575 patients that smoking status was the only clinical factor
that affected the risk of gradeZ3 RP independent of dosimetric
factors. Patientswhohad never smoked (“nonsmokers”) had the
highest incidence RP (37%), whereas patients who reported
being smokers at the time of diagnosticworkup (“smokers”) had
the lowest incidence (14%).10 Indeed, smoking damaged lung,
that is, “dead lung”may not be as sensitive to radiation injury as
healthy, well-perfused lung, as it is mostly ﬁbrotic or has
nonfunctional airspace. Tobacco-induced immunosuppression
could be another possible explanation for this effect.21,22
However, theseﬁndings should innowaybe taken to encourage
smoking among patients, because smoking is a risk factor for
poorer survival.23,24 In fact, smokers often have limited pulmo-
nary reserve and are at a greater risk todevelop respiratory failure
even after a modest reduction of lung function.Pre-Existing Lung Disease
There are 2 types of pre-existing lung disease that might
inﬂuence the risk of RILT: interstitial lung disease (ILD) and
chronic obstructive pulmonary disease (COPD), which includespulmonary emphysema. Clinically, acute exacerbation of pre-
existing lung disease following RT can confound the deﬁnitive
diagnosis of RP.25
Patients with pre-existing ILD appear to bemore susceptible
to acute lung injury after RT, resulting in acute ILD exacer-
bation. It has been reported that for patients with pre-existing
interstitial changes on computed tomography (CT), the
incidence of RP Z grade 3 was signiﬁcantly increased to
26% as compared with 3% for those with normal lung.26 In
another study, grades 4-5 RP occurred in 57% of patients with
interstitial pneumonitis as compared with 2% of those with-
out.27 Ueki et al recently reported that pre-existing ILD was a
signiﬁcant risk factor for symptomatic and severeRP in patients
with non–small cell lung cancer (NSCLC) treated with stereo-
tactic body RT (SBRT). The incidence ofZG2 RP (55.0% vs
13.3%) andZG3RP (10.0% vs 1.5%)was signiﬁcantly higher
in patients with ILD (þ) than without ILD ().28 Yamaguchi
et al29 reported that subclinical ILD was not a predictor of
gradeZ2 RP in patients treated with thoracic SBRT, but the
rate of extensive RP beyond the irradiated ﬁeld was signiﬁ-
cantly higher in the patients with subclinical ILD. Therefore,
caution must be taken when considering RT for patients with
ILD, particularly interstitial pneumonitis. Safe dosimetric dose
limits of standard practice may not be safe for this population.
There are no consistent results regarding the predictive role of
COPD on RILT. Some studies showed that the presence of
COPD signiﬁcantly increased the risk of RILT,30,31 whereas
others did not.10,14,29,32 In Kimura 's study, using CT classiﬁca-
tion of pulmonary emphysema, the incidence of RP increased
signiﬁcantly as the emphysema grade increased. In patients with
emphysema grades 0, 1, 2, and 3 or greater, the incidence of RP
was 16.5%, 9.1%, 8.6%, and 54.0%, respectively.31 Using PF
(forced expiratory volume at the ﬁrst second [FEV1] and forced
vital capacity) to grade COPD, Takeda et al found severe COPD
did not increase the risk of gradeZ2 RP in patients with lung
cancer treated with SBRT. Patients with COPD tended to have
milderRP than thosewithnormal lungs.32At least 2 factors need
to be considered for the effect of COPD on a patient's risk for
RILT. On one side, emphysematous lung is often ﬁlled with
trapped air, contains less lung parenchyma to radiation expo-
sure. On the other side, patients with COPD can also have
borderline lung function so that they have limited tolerance to
any reduction in lung function. In all, contrary to patients with
ILD, patients with emphysema might tolerate RT better than
what has been traditionally believed. COPD is not a contra-
indication to deﬁnitive RT. The tolerance of patientswithCOPD
may be associated with the functional level of the lung.Pulmonary Function
Adequate PF is required for cancer treatment such as thoracic
surgery to decrease the risk of pulmonary complications, and
patients with very poor PF are generally considered unﬁt for
surgery. Traditionally, PF was also used to select patients for
RT. PF parameters such as percent predicted value of FEV1,
forced vital capacity, and diffusion capacity of lung for carbon
monoxide (DLCO) have been used as the primary indicators of
F.-M. (Spring) Kong and S. Wang102whole lung function. Earlier Radiation Therapy Oncology
Group (RTOG) studies limited patients with FEV1 of greater
than 0.85, later to 0.75 L for RT protocol participation.
However, there is no consistent evidence to support the
association between PF parameters and RILT. A few studies
reported that impaired baseline PF predicted higher risk of
symptomatic RILT, in which lower baseline levels of absolute
FEV1,11,33 or FEV1%,34 DLCO%,35 or PaO2
36 were signiﬁ-
cantly associated with the risk of RILT. Other studies have not
shown signiﬁcant correlations between PF and RILT.10,12,37-40
Interestingly, a recent study with 260 patients showed that
lower FEV1 may associate with reduced risk of RILT; patients
with symptomatic RILT had marginally higher FEV1 than
those without (71.7% vs 65.9% of predicted, P¼ 0.077).18 It
is of course possible that the patients included in the studies
had already been selected by physicians, and typically those
who had very poor PF were not offered deﬁnitive RT. The jury
is still out whether poor lung function is associated with high
or lower risk of RILT.
The physiological changes in PF because of RT for patients
with lung cancer are quite complex. Tumor shrinkage after RT
could alleviate bronchial obstruction or compression, thus
improve lung ventilation. As noted previously, impaired lung
may be less susceptible to radiation damage compared with
normal lung, which has better cellular oxygenation. An early
prospective study showed that patients with better (450%)
baseline FEV1 tended to lose signiﬁcant lung function after RT,
whereas most of those with poor FEV1 before RT underwent
only amild decrease or even an improvement in PF.41 A recent
study reported more reduction in diffusing capacity than
ventilation after RT.42 DLCO fell in most patients after RT,
and pre-RTDLCOr50%was associatedwith greater post-RT
declines in DLCO, whereas the FEV1 per unit of vital capacity
showed an increase and decrease after RT in a similar
percentage of patients.
The global lung function is a result of a combination of
regional function of different functioning parts of the lung.
Based on regional function level, cause of dysfunction, and
potentially recoverability, thewhole lung canbedivided into the
following different regions: normal functioning lung, tempora-
rily dysfunctional lung caused by tumor, and unrecoverable
nonfunctioning or low-functioning lung caused by pre-existing
lung disease. Through regional functionmapping by ventilation
(V) or perfusion (Q) single-photon emission CT, we can
understand more about the radiosensitivity of the different
functioning lungs. A study from our group43 indicated that the
normal functioning lung is most susceptible to RT damage, and
approximately 20% of patients had worsened function in this
region after RT; unrecoverable nonfunctioning or low-
functioning lungs only experienced worsened regional function
in 3.6% and 9.3% of patients—they cannot be injured more
because they are already or nearly “dead”; and 55% of
temporarily dysfunctional lung caused by tumor can partially
or completely recover to normal function levels. This ﬁnding
indicated that lung is not a uniformorgan, instead it has regional
differences in function, andpatientswith lung cancer experience
heterogeneous changes to RT in different functioning regions.
Regional function mapping, especially accessing combinedregional V/Q function,44 or optimizing the treatment plan
accordingly45 might be more helpful in guiding RT.Tumor Factors and Tumor
Location
Tumor location may inﬂuence the risk of RILT based on the
ﬁndings in several studies, indicating patients with tumors in
the lower lobes had higher risk of RP,13,46-48 though some
inconsistent ﬁndings exist.49 Bradley et al13 reported a signiﬁ-
cantly greater risk for patients with tumors located in the
inferior part of the lung. A study by Seppenwoolde et al46 also
found that irradiation of caudally located lung tumors resulted
in a greater risk of RP than irradiation of tumors located in other
parts of the lungs, and the incidence of RP was 11% and 40%
for cranial and caudal tumors, respectively. Similarly, another
study showed when the lower part of the lung was included in
the radiation site, the incidence of pneumonitis was 70%
compared with 20% for other lobes.47 The MLD of the lower
portion instead of the upper portion of the lungs was
signiﬁcantly correlated with grade Z3 RP.50 A pooled meta-
analysis conﬁrmed that middle or inferior part of the lung
tumors is associated with increased risk of RP compared with
upper lung locations.8 Increased RP risk with lower tumor
locations possibly reﬂects radiosensitivity differences among
different lung regions, owing to a greater density of target cells
in the lower part of the lung51 or strong out-of-ﬁeld effect of
irradiation of lower part of the lung.52 The other explanations
may be more physiologically pronounced perfusion and
ventilation of the lower part of the lung (better oxygenation)
or increased tumor motion during RT causing more normal
lung to be irradiated at a lowdose. Therefore, caution should be
taken when lower part of the lung is included in the RT ﬁeld.Tumor Volume and Tumor Stage
Tumor volume and tumor stage themselves may not be
important in predicting the risk of RILT. Some studies showed
T2 tumors had a higher rate of G2 RP than T1 in patients
treated with SBRT (17.9% vs 4.4%, P ¼ 0.02),53 but other
studies showed ﬁeld size (Z200 cm2 vs o200 cm2)47 or
tumor volume (cutoff atmedian)was not associatedwithZG2
RP.54 There are some data suggesting that stages I-II disease
predicted lower risk of RILT than stage III20 or stages III-IV
did55; however, most found that tumor stage was not
associated with the risk of ZG2 RP5,18,33,56,57 or ZG3
RP.4,10,11,14,36,58-61 It is understandable that the effect of tumor
volume and stagemay be confounded by other risk factors and
also depends on the lung dosimetry, which is related to an
individual 's lung volume54: larger or more advanced tumors
do not necessarily result in poorer lung dosimetry result.
Previous Radiation
For patients who develop recurrent or secondary lung tumors
after previous thoracic RT, reirradiation is often the only
Nondosimetric risk factors for RILT 103treatment option. Under such a circumstance, RT-associated
risk of serious RILT should be considered. The literature is
limited on this topic. A study showed 1 of 19 patients
developed grade 3 RP, and a survival beneﬁt was found for
those who had longer intervals between initial RT and
reirradiation (412 months) and good performance status
(Eastern Cooperative Oncology Group Performance Status
[ECOG PS] scores of 0-2).62 Other studies showed grades 1-2
RP in 22% of patients and no grade 3 or greater RP in 23
patients63 or grades 2-3 RP in 19 of 34 of patients.64 Recently,
Liu et al analyzed 72 patients treated with stereotactic ablative
radiation therapy (SABR) after previous thoracic RT and found
20.8% of patients developed gradeZ3 RP. ECOGPS scores of
2-3 before SABR, FEV1r 65% before SABR, V20Z 30% of
the composite plan, and an initial planning target volume in
the bilateral mediastinum were signiﬁcantly associated with
increased risk of RP.65 Therefore, previous thoracic RT is not a
contraindication for RT when recurrent or secondary lung
tumors occurred. However, patient selection criteria should be
strict, requiring consideration of other risk factors such as PS,
pulmonary function, complete lung dosimetry including V20
of the composite plan, and initial radiation area for lung safety.
For such cases, lung functional mapping using V/Q single-
photon emission CT is recommended to avoid further damage
of the functioning lung.44,45Previous Chemotherapy
There are conﬂicting results on the inﬂuence of previous
chemotherapy on the risk of RILT. For an individual patient
with bulky tumor, induction chemotherapy may shrink the
tumor, thus decrease the radiation ﬁeld and the volume of
normal lung and the risk of RILT. A dosimetric analysis of 25
patients with NSCLC showed that approximately 30% of
patients had at least a 20% reduction in tumor volume after
induction chemotherapy, which translated into a small statisti-
cally signiﬁcant reduction (5%) in the predicted risk of RP.66
However, a retrospective analysis of 223 patients by Wang
et al14 did not show a signiﬁcant association in the risk of grade
Z3 RP between patients with and without induction chemo-
therapy. In contrast, in a model using decision tree analysis,
another study demonstrate that chemotherapy before RTwas a
risk factor for gradeZ2 RP.16 Some patientsmay also progress
during induction chemotherapy. Induction of mitomycin C
was found to increase the risk of RP: gradeZ2 RP was 31.2%
among patients who received induction mitomycin C and
10.6% among those who did not.30 In summary, the use of
induction chemotherapy should be on an individual basis, and
there is no consistent evidence regarding its use and the risk
of RILT.Treatment Factors
The most important treatment factor is radiation lung dosim-
etry, which is not the focus of this review. In brief, MLD and
V20 are the most frequently reported and the most reprodu-
cible lung dosimetric factors. It is recommended to limit V20 tor30%-35%, and MLD to r20-23 Gy (with conventional
fractionation), if one wants to limit the risk of RP tor20% in
patients with NSCLC treated with deﬁnitive RT.67 One must
note that each dosimetric parameter is highly correlated with
one another.37 There is an unanswered question of what is
associated with higher risk of RILT: “a little (dose) to a lot
(lung),” vs “a lot (dose) to a little (lung).” Tucker et al68 found
that given the sameMLD, high doses to small lung volumes (“a
lot to a little”) were worse than low doses to large volumes (“a
little to a lot”). In addition, functional dosimetric parameters
may provide better predictive outcome than physical dosi-
metric factors, whichwere reported in very limited studieswith
small size of patients.33,69,70
The other important treatment factor is concurrent chemo-
therapy with RT (CCRT), which is the standard of care in
patients with a locally advanced NSCLC or limited-stage small
cell lung cancer. CCRT is often considered to be a risk factor for
RILT, as it is a more aggressive form of treatment. Indeed,
patients treated in early RTOG trials showed CCRT signiﬁ-
cantly increased gradeZ3 late lung toxicity as compared with
sequential chemotherapy and RT (20% vs 10%).71 Agents
associated with known risk to escalate RILT such as bleomycin
and gemcitabine are not used in concurrent practice anymore.
Ameta-analysis by Palma et al based on individual patient data
suggested that the choice of concurrent chemotherapy regimen
played an important role in RP risk, particularly in the elderly.
The risk of gradeZ2 RP for patients treated with combination
of concomitant carboplatin and paclitaxelwith RTwas 3.3-fold
that of cisplatin and etoposide with RT. Patients 465 years
receiving concurrent carboplatin-paclitaxel regimens had the
highest risk of RP.72 In another study with 369 patients
analyzed, a higher rate of grade Z3 RP was also found for
concurrent docetaxel-cisplatin schedule (18.4%) than that for
concurrent vinorelbine-cisplatin schedule (9.5%).4 However, a
weekly carboplatin-paclitaxel regimen remains in common use
in practice and RTOG trials, such as RTOG0617 and
RTOG1107. The RP rate was acceptable from preliminary
report of RTOG0617. Nevertheless, concurrent taxane chemo-
therapy regimens may increase the risk of RP and should be
chosen carefully, maybe with stricter dose constraints of
the lung.Biological Factors or Genetic
Phenotypes
Individual genetic phenotypes determine the intrinsic radio-
sensitivity of lung to radiation. The pathogenesis of RILT may
involve direct radiation cytotoxicity to normal lung tissue,
secondary inﬂammatory changes, and ﬁbrotic remodeling.73
Thus, genetic variation in key genes in DNA repair, inﬂam-
mation, and oxidative stress pathways may ameliorate or
exacerbate the effects of a given radiation dose to the lungs.
In recent years, the candidate gene single nucleotide poly-
morphism (SNP) approach has been used in several studies to
evaluate the intrinsic radiosensitivity of lung to radiation. SNPs
in a series of genes associated primarily with radiation-related
F.-M. (Spring) Kong and S. Wang104processes were genotyped in patients with lung cancer (white
or Han Chinese) who developed RILT (Table 1).
There were 2 studies that provided independent replication
cohorts for validation. Pang et al55 showed patients with lung
cancer who had the CC genotype heat-shock protein B1 (as
opposed to CG or GG) had a higher probability of severe RP
after RT in both the training and validation data sets. Pu et al74
further evaluated the functional correlation of SNPs with
radiosensitivity. In his study, 11,930 SNPs from 904
inﬂammation-related genes were included in the discovery
analysis. Of these, 1321 were signiﬁcantly associated with RP.
Overall, 9 SNPs were signiﬁcantly associated with RP in the
validation population. These SNPs were also selected to assess
for functional correlation with radiation sensitivity via the
lymphoblastoid cell line model system that incorporates base-
line host gene expression and cytotoxicity following RT. In
total, 45 SNPs in 3 genes (PRKCE,DDX58, and TNFSF7) were
found to be signiﬁcantly associated with radiation response,
which are more than 5.8 that would be expected by chanceTable 1 Studies Evaluating SNPs and Radiation-Induced Lung Toxicit
Study Patients
No.
End Point Gene Associa
Toxi
Pu et al74 421 ZG2 RP CDC2 (rs10711) a
DDX58 (rs1179534
(rs7865082)
FGF5 (rs3733336)
ETS2 (rs2298560)
LIMS1 (rs1246901
GHR (rs4292454)
TFEB (rs13202921
Wen et al9 362 ZG3 RP LIN28B (rs314280
LIN28B (rs314276
Pang et al55 271 ZG3 RP HSPB1 (rs2868371
Xiong et al59 362 ZG3 RP ATM (rs189037) an
Kelsey et al80 39 Radiologic
change
XRCC1 (rs25487)
BRCA1 (rs16942)
Mak et al56 136 ZG2(G3) RP MTHFR (rs180113
Yin et al60 195 ZG3 RP LIG4 (rs1805388)
Yin et al81 193 ZG3 RP VEGF (rs2010963)
Niu et al58 46 ZG3 RP TGFβ1 (rs1146634
Yin et al20 261 ZG2 RP APEX1 D148E GG
XRCC1 Q399R AA
Yang et al75 253 ZG2 RP P53 Arg72Pro
Hildebrandt
et al19
173 ZG2 RP IL1A (rs1800587/r
IL-8 (rs4073)
TNF (rs1799724)
TNFRSF1B (rs1061
MIF (rs7555622)
IL4 (rs2243250)
IL4R (rs2070874)
IL13 (rs10800925)
IL13 (rs20541)
NFKBIA (rs179998
NOS3 (rs1799983
Zhang et al57 253 ZG2 RP ATM (rs189037) an
Yuan et al61 164 ZG2(G3) RP TGFβ1 (rs1982073
Abbreviations: BER, base excision repair; NHEJ, nonhomologous end joininalone. DDX58 Rs11795343 was consistently signiﬁcantly
associated with increased risk of developing RP.
The risk of RP increased as the number of unfavorable
genotypes increased. In a study by Hildebrandt et al,19 12
common polymorphisms were found to be signiﬁcantly
associated with the risk of RP. Compared with patients with
0-2 risk genotypes, the risk of RP was 13.3-fold and 69.4-fold
for those carrying 3 and 4 or more unfavorable genotypes,
respectively. In a study by Yang et al,75 compared with the
absence of unfavorable genotype, the risk of RP increased with
presence of P53 72Arg/Arg genotype (hazard ratio [HR] ¼
2.24) or ataxia telangiectasia mutated (ATM)–111A allele (AA
or GA genotype) (HR ¼ 2.36). The presence of both risk
genotypes, that is, the P53 72Arg/Arg and the ATM-111AA or
GA genotypes, had a signiﬁcantly greater risk of RP (HR ¼
6.17).
Incorporation of genetic patient information in the form of
SNPs from a relatively small set of genes canmarkedly improve
the ability of the Lyman-Kutcher-Burman MLD model toy
ted With Lung
city
Gene Function
nd (rs1871445) Inﬂammation
3) and
6)
)
) RNA binding protein
)
) Oxidative stress pathways
d (rs228590) DNA repair
DNA repair
1) Oxidative stress pathways
DNA repair (NHEJ)
and (rs3025039) Angiogenesis
5) Inﬂammation
DNA repair (BER)
Cell-cycle regulation, apoptosis, and DNA
repair
s17561) Inﬂammation
622)
3)
)
d (rs373759) DNA repair
) Inﬂammation
g.
Nondosimetric risk factors for RILT 105predict RP risk. In Tucker 's study, with 5 SNPs in the TGFβ,
TNFα, VEGF, XRCC1, and APEX1 genes, it was possible to
distinguish cohortswith450% risk vso10% risk of RPwhen
exposed to high MLDs.76 Vinogradskiy et al77 found a model-
generated personalized lung-dose limit from dosimetric con-
straints, and SNPs could result in a clinically signiﬁcant change
to the prescription, whichwould help to determine howmuch
dose can be safely delivered to the tumor and normal tissues on
an individual basis.
Future studies using a genome-wide association studies
approach with sufﬁcient numbers of patients to investigate
SNPs associated with RILT may ﬁnd more accurate RILT-
related genotypes than the target gene approach. However, in
addition to geneticmakeup, epigenetics and other proteins also
play a role in determining the individual risk of RILT. For
example, our group identiﬁed serummicroRNA expression (Bi
et al, unpublished data) and plasma levels of proteins78,79 such
as C4b-binding protein α chain, complement C3, and
vitronectin as predicting risk factors for RILTusing a proteomic
approach, and these biomarkers play important roles in the
inﬂammatory response.Biological Factors or Cytokines
Inﬂammatory cytokines released by cells trigger inﬂammation
and respond to infections, and their levels have been incon-
sistently shown to serve as early surrogate markers for RILT.Table 2 Studies Evaluating the Association of Plasma Cytokines With
Study Patients
No.
End Point
Stenmark
et al98
58 ZG2 RP or
symptomatic
pulmonary ﬁbrosis
IL-8 pre-RT and at
ratios at 2 and 4
Zhao et al99 165 ZG2 RILT TGF-β1 ratio at 4-5
Kim et al89 34 ZG2 RP Change of TGF-β1
Zhao et al88 26 ZG2 RILT TGF-β1 ratio at 4 w
Evans et al90 121 ZG1 RP TGF-β1 ratio at en
Hart et al97 55 SRILT IL-8 at pre-RT (Po
De Jaeger
et al95
68 ZG2 RP TGF-β1 ratio at 4-6
relation)
Novakova-
Jiresova
et al96
46 Symptomatic RP TGF-β1 level (P4
Fu et al87 103 Symptomatic RILT TGF-β1 level at en
Anscher
et al83
73 Symptomatic RP TGF-β1 level at en
*These studies used procedures of plasma preparation to minimize the plate
time and temperature of blood setting before centrifuge, and avoiding pla
†Plasma samples may have been contaminated by platelets, as they used 12
supernatant.Blood inﬂammatory cytokines such as TGF-β1, interleukin 8
(IL-8), and Krebs von den Lungen-6 have been reported to
predict RILT in some studies.
Although it is likely that no single molecule or cytokine will
provide adequate predictive power in all cases, TGF-β1—a
prototype of multifunctional regulators of cell growth and
differentiation, a proinﬂammatory and proﬁbrotic cytokine—
has been singled out to play a pivotal role in promoting lung
damage via various pathways. TGF-β1, normally present in a
latent form, can be activated by ionizing radiation–induced free
radicals. ActivatedTGF-β1directly stimulates connective tissue
formation and decreases collagen degradation and plays an
important role in the inhibition of epithelial cell proliferation
and the development of tissue ﬁbrosis and radiation-induced
inﬂammation. Increased local TGF-β1 expression is accom-
panied by an elevated plasma concentration. The predictive
value of TGF-β1 for humanRILTwasﬁrst reported by Anscher
et al82 in individuals with advanced breast cancer treated by
high-dose chemotherapy and autologous bone marrow trans-
plantation. Further studies including those from our group
demonstrated that changes in plasma TGF-β1 levels may
identify individuals at high risk for the development of
RILT.83-86 A persistently elevated plasma TGF-β1 above base-
line level at the end of RT,83,87 the ratio of TGF-β1 level over
baseline during RT,88 and a signiﬁcant elevation of TGF-β1
level at 4 weeks after RT89 were signiﬁcantly associated with
symptomatic RILT. A return of the plasma TGF-β1 to normal
level could identify patients who would not develop RP.83 AnRadiation-Induced Lung Toxicity
Cytokines (P value) Sample
Handling
Process
weeks 2 and 4 during RT (Po 0.01); TGF-β1
wk during RT or baseline (P¼ 0.41 and 0.26)
Platelet-poor
plasma*
wk during RT or baseline (Po 0.001) Platelet-poor
plasma*
level during RT (P ¼ 0.0001) Platelet-poor
plasma*
k during RT or baseline (P ¼ 0.015) Platelet-poor
plasma*
d-RT or baseline (Po 0.001) Platelet-poor
plasma*
0.005) Platelet-poor
plasma*
wk during RT or baseline (P ¼ 0.01 inverse Plasma†
0.05) Plasma†
d-RT (P ¼ 0.007) Platelet-poor
plasma*
d-RT (Po 0.05) Platelet-poor
plasma*
let contamination or degradation by using enough gravities, controlling
telet contamination by using top layer of plasma.
00 or 1000g, which was not enough to remove the platelets in plasma
F.-M. (Spring) Kong and S. Wang106earlier study from Fu et al87 also reported that the combination
of end-RT-to-pre-RT TGF-β1 level and lung V30 could stratify
patients into low-, intermediate-, and high-risk groups, and
patients with both high end-RT-to-pre-RT TGF-β1 level and
V30 Z 30% had the highest risk of SRILT at 43%. Further-
more, study from that group using grade Z1 RP as an end
point found TGF-β1 was not predictive of RILT except for the
group of patients with a high V30. Among patients with lung
V30 4 30%, those with higher end-RT-to-pre-RT TGF-β1
ratio had a signiﬁcantly higher incidence of RILT.90 Others
reported that TGF-β1 levels in the bronchial alveolar lavage
ﬂuid were also predictive of RILT.91
One must note that the role of TGF-β1 on RILT can be
confounded by tumors, as circulating TGF-β1 levels may be
produced by lung tumors. The dynamics of the plasma TGF-
β1 could be a marker of RILT as well as a marker of tumor
response to treatment.92 Elevation of plasma TGF-β1 levels
in patients with lung cancer may also contribute to individ-
ual inabilities to normally process TGF-β1.93 These individ-
uals have often lost the mannose 6-phosphate or insulinlike
growth factor 2 receptor, a key factor associatedwith TGF-β1
activation. As TGF-β1 is richly stored with platelets, careful
sample handling is important to avoid artiﬁcially elevated
plasma TGF-β1 level from platelet contamination or degra-
dation.93,94 Some studies reported that plasma TGF-β1 was
not signiﬁcantly associated with the risk of RILT95,96; some
of these studies applied sample handling procedures that
were not controlled for platelet contamination (Table 2).
Nevertheless, a meta-analysis including 7 studies showed
end-RT-to-pre-RT TGF-β1 ratio Z1 was a risk factor for
RP.1 Plasma TGF-β1 level, particularly the radiation-induced
elevation, would possibly allow for identifying patients at
high risk for RILT.
A complex cytokine network is involved in the process of
RILT. A comprehensive illustration of cytokine cascade is
beyond the scope of this review, but a few studies reporting
the potential for combining multiple cytokines in predicting
the risk of RILT are noted. Plasma inﬂammatory cytokine
proﬁling assays were performed in 55 patients analyzing the
levels of 17 cytokines before RT, but the study failed to
identify a speciﬁc signature to predict the risk of RILT, and
only lower baseline levels of IL-8 were associated with an
increased risk of developing symptomatic RILT.97 A model
combining pretreatment levels of multiple circulating cyto-
kines and MLD may more accurately predict RILT. Our
group98 reported that combining IL-8, TGF-β1, and MLD
into a single model yielded an improved predictive ability
compared with either variable alone. Combination of cyto-
kines and other parameters could also serve as a prescreening
tool for patients before RT. By prescreening patients for
serum Krebs von den Lungen-6 and surfactant protein-D as
biomarkers and considering ILD on CT scans, appropriate
patients were selected for SBRT. As a result, the frequency of
grades 4-5 RP in a Japanese study has shown a decrease, from
18.8% before 2005 to 3.5% after 2006.27 Because these
parameters can be obtained during the early course of RT or
at baseline, this model has the potential to serve as a
predictive tool to prescribe personalized RT.Summary
Older patients, pre-existing ILD, tumor located in lower lung,
concurrent taxane chemotherapy, several SNPs phenotypes,
radiation-induced elevation in TGF-β1, and lower levels of IL-
8 have been shown to increase the risk of RILT, in addition to
the standard parameters of lung dosimetry. However, a
consistent predictivemodel for the risk of RILT is not available.
There is potential in investigating the intrinsic sensitivity of
individual patients by focusing on genetic and epigenetic
characteristics, and combining them with clinical and dosi-
metric factors in a model, but large numbers of patients and
validations are needed.Acknowledgments
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